Duke-NUS Pancreatic Cancer Breakthrough: Molecular ‘Switch’ Discovery Promises More Treatable Tumors

Understanding the Pancreatic Cancer Challenge

Pancreatic cancer, particularly pancreatic ductal adenocarcinoma (PDAC), remains one of the most formidable malignancies worldwide. In Singapore, it ranks as the ninth most common cancer but claims the fourth spot among cancer-related deaths, with a five-year survival rate hovering around 10 to 12 percent globally and similarly low locally. 65 68 This dismal prognosis stems from late diagnosis, aggressive tumor behavior, and resistance to standard chemotherapy regimens like gemcitabine. The disease's heterogeneity adds another layer of complexity, as tumors exhibit diverse molecular profiles that influence treatment response.

Recent statistics underscore the urgency: incidence rates are rising in Asia-Pacific high-income regions, including Singapore, driven by aging populations and lifestyle factors such as diabetes and obesity. 70 For instance, pancreatic cancer accounts for about 3 percent of all cancers in Singapore, affecting males slightly more than females. Early detection remains rare, with most cases diagnosed at advanced stages where surgical resection—the only potentially curative option—is not feasible.

Duke-NUS Researchers Identify the Molecular 'Switch'

A groundbreaking study from Duke-NUS Medical School has pinpointed a molecular "switch" that dictates whether PDAC cells adopt a treatable or resistant state. Led by Professor David Virshup, head of the Programme in Cancer & Stem Cell Biology, the team revealed that oncogenic KRAS/ERK/JUNB signaling suppresses GATA6, a transcription factor essential for pancreatic cell differentiation. 72 61

KRAS mutations occur in over 90 percent of PDAC cases, perpetually activating the ERK pathway. This hyperactivation stabilizes JUNB, which in turn represses GATA6 expression. High GATA6 levels characterize the "classical" subtype—more organized, epithelial-like cells that respond better to chemotherapy. Conversely, low GATA6 triggers a shift to the "basal-like" subtype: mesenchymal, invasive cells evading treatment.

"We have known that pancreatic cancer cells can switch between these two states," Prof Virshup explained. "What we didn’t understand was the mechanism driving that switch." 72

Decoding the Classical vs. Basal-Like Subtypes

PDAC tumors are broadly classified into classical and basal-like subtypes based on gene expression profiles. Classical tumors maintain ductal features, showing better prognosis and chemotherapy sensitivity. Basal-like tumors, however, lose differentiation, gaining stem-like properties that promote metastasis and drug resistance.

• Classical subtype: High GATA6, organized structure, responsive to gemcitabine-based therapy.
• Basal-like subtype: Low GATA6, disorganized, poor response, higher mortality.

This plasticity—cells toggling states—explains why initial responders often relapse. The Duke-NUS discovery links this to the KRAS-ERK-JUNB-GATA6 axis, offering a mechanistic blueprint.Explore research jobs advancing cancer subtype studies.

The KRAS/ERK/JUNB-GATA6 Pathway Step-by-Step

The pathway operates as follows:

1. Mutant KRAS constitutively signals through ERK.
2. Activated ERK phosphorylates and stabilizes JUNB transcription factor.
3. JUNB binds GATA6 promoter, suppressing its transcription.
4. Reduced GATA6 disrupts differentiation programs, shifting to basal-like state.
5. Result: Enhanced invasion, metastasis, chemotherapy evasion.

This step-by-step elucidation, validated in cell lines, organoids, and patient-derived xenografts, paves the way for precision combinations. 72

Research Methodology: From Bench to Insight

The Duke-NUS team employed CRISPR genetic screens to identify suppressors of GATA6, revealing ERK/JUNB. They integrated single-cell RNA sequencing, chromatin immunoprecipitation, and pharmacological interventions. Patient samples confirmed higher GATA6 correlates with better outcomes.

Key tools included DeeVid AI for enhanced imaging analysis. Findings were published in the Journal of Clinical Investigation (DOI: 10.1172/JCI191370). 72

Prof Lok Sheemei, Interim Vice-Dean for Research, highlighted: "These findings provide a mechanistic explanation for why tumours respond poorly to chemotherapy."Research assistant roles in oncology at Singapore institutions.

Treatment Implications: Reversing Resistance

The switch suggests combining KRAS/ERK inhibitors with chemotherapy could convert basal-like tumors, improving outcomes. Early data shows restored GATA6 sensitizes cells 2-3 fold. Ongoing trials (e.g., KRAS G12C inhibitors) may incorporate GATA6 biomarkers.

In Singapore, where PDAC mortality burdens healthcare, this aligns with national precision oncology pushes. Broader KRAS-driven cancers (colorectal, lung) may benefit similarly.

Prof Patrick Tan, Dean, emphasized: "Understanding how cancer cells switch states gives us a more strategic way to design combination treatments." 61 Singapore higher education and research opportunities.

Duke-NUS Medical School: Hub of Biomedical Innovation

Duke-NUS, a collaboration between Duke University and National University of Singapore, excels in translational research. Established in 2005, it trains clinician-scientists via MD-PhD programs, fostering breakthroughs like this GATA6 study.

Prior contributions include Wnt resistance mechanisms in PDAC.Duke-NUS Wnt study. The school's Programme in Cancer & Stem Cell Biology drives such advances, positioning Singapore as Asia's biomed leader.

Careers abound: from postdocs to faculty in cancer biology. Postdoc positions in Singapore higher ed.

Pancreatic Cancer Landscape in Singapore

Singapore sees ~500-600 new PDAC cases yearly, with rising trends tied to diabetes (prevalent in 11% adults). National efforts like SCREEN Singapore promote early detection, but survival lags.

• Incidence: 3.4% males, 2.8% females.
• Mortality: 4th leading cancer cause.
• Challenges: Late-stage diagnosis (80%+), limited surgery eligibility (20%).

Duke-NUS findings bolster Singapore's precision medicine ecosystem, integrating AI and genomics. 67

Broader Impacts and Future Outlook

Beyond PDAC, the switch informs resistance in other KRAS-mutant cancers. Future: GATA6 as biomarker for trials, JUNB inhibitors development. Singapore's A*STAR and NUHS partnerships accelerate translation.

Clinical trials: Expect KRAS combo studies soon. Researchers eye epigenetic modifiers to boost GATA6.

For academics: Opportunities in crafting CVs for biomed roles.

Career Pathways in Singapore's Cancer Research

Duke-NUS exemplifies Singapore's thriving research scene. Roles span postdocs, lecturers, professors in oncology. With funding from NMRC and global ties, it's ideal for ambitious scientists.

• Lecturer jobs in biomedical sciences.
• Professor positions at Duke-NUS/NTU/NUS.
• Faculty openings in cancer biology.

Explore Rate My Professor for insights on mentors.

Photo by Chromatograph on Unsplash

Conclusion: Hope on the Horizon

The Duke-NUS molecular switch discovery heralds a new era for PDAC therapy, potentially transforming resistant tumors into treatable ones. As Singapore invests in higher education and research, institutions like Duke-NUS lead globally. For researchers, job seekers: higher-ed-jobs, university-jobs, higher-ed-career-advice, rate-my-professor, post-a-job offer gateways to this dynamic field.